Symbols / ARTV Stock $10.32 -8.67% Artiva Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
ARTV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Fred Aslan M.D.
Exch · Country NGM · United States
Market Cap 255.08M
Enterprise Value 158.01M
Income -83.86M
Sales —
FCF (ttm) -49.24M
Book/sh 4.53
Cash/sh 4.37
Employees 104
Insider 10d —
IPO Jul 19, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.17
PEG —
P/S —
P/B 2.28
P/C —
EV/EBITDA -1.81
EV/Sales —
Quick Ratio 8.31
Current Ratio 8.61
Debt/Eq 9.95
LT Debt/Eq —
EPS (ttm) -3.43
EPS next Y -2.48
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-10
Earnings (prior) 2026-03-10
ROA -32.97%
ROE -56.55%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 24.72M
Shs Float 4.27M
Insider Own 27.71%
Instit Own 68.84%
Short Float 1.47%
Short Ratio 0.78
Short Interest 148.49K
52W High 14.53
vs 52W High -28.97%
52W Low 1.47
vs 52W Low 602.04%
Beta —
Impl. Vol. —
Rel Volume 0.67
Avg Volume 229.01K
Volume 153.17K
Target (mean) $17.00
Tgt Median $18.00
Tgt Low $10.00
Tgt High $23.00
# Analysts 5
Recom Strong_buy
Prev Close $11.30
Price $10.32
Change -8.67%
About

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.00
Mean price target
2. Current target
$10.32
Latest analyst target
3. DCF / Fair value
$-35.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.32
Low
$10.00
High
$23.00
Mean
$17.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-11 reit Needham Buy → Buy $18
2025-11-12 main HC Wainwright & Co. Buy → Buy $15
2025-10-17 main Wedbush Outperform → Outperform $23
2025-10-17 reit Needham Buy → Buy $18
2025-05-15 main Needham Buy → Buy $18
2025-04-08 reit Needham Buy → Buy $23
2025-03-26 reit HC Wainwright & Co. Buy → Buy $20
2025-03-25 reit Wedbush Outperform → Outperform $18
2025-03-25 main Cantor Fitzgerald Overweight → Overweight $20
2025-03-25 reit Needham Buy → Buy $23
2024-12-30 init HC Wainwright & Co. — → Buy $20
2024-11-13 reit Needham Buy → Buy $23
2024-08-30 reit Needham Buy → Buy $23
2024-08-13 init Needham — → Buy $23
2024-08-13 init Wedbush — → Outperform $18
2024-08-13 init Cantor Fitzgerald — → Overweight $23
2024-08-13 init TD Cowen — → Buy —
2024-08-13 init Jefferies — → Buy $21
News
RSS: Latest ARTV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 HUSTON THAD ALLEN Chief Financial Officer — 220,000 $0.00 $0
2026-02-13 BUSH JENNIFER KINSBRUNER Chief Operating Officer — 117,300 $0.00 $0
2026-02-13 HORAN CHRISTOPHER Chief Operating Officer — 117,300 $0.00 $0
2026-02-13 ASLAN FRED M.D. Chief Executive Officer — 366,850 $0.00 $0
2026-02-13 RAYMON HEATHER Officer — 46,000 $0.00 $0
2026-02-13 BANERJEE SUBHASHIS M.D. Officer — 102,000 $0.00 $0
2025-12-15 ASLAN FRED M.D. Chief Executive Officer — 3,187 $3.30 $10,517
2025-12-12 BUSH JENNIFER KINSBRUNER Chief Operating Officer — 84,877 $0.00 $0
2025-12-12 HORAN CHRISTOPHER Chief Operating Officer — 107,156 $0.00 $0
2025-12-12 ASLAN FRED M.D. Chief Executive Officer — 869,136 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.25
-99.25%
33.49
+579.21%
4.93
Operating Revenue
0.00
-100.00%
0.25
-99.25%
33.49
+579.21%
4.93
Operating Expense
89.81
+32.99%
67.53
+5.25%
64.16
-0.92%
64.76
Research And Development
69.54
+38.17%
50.33
+0.15%
50.25
+14.25%
43.98
Selling General And Administration
20.27
+17.81%
17.20
+23.67%
13.91
-33.04%
20.78
General And Administrative Expense
20.27
+17.81%
17.20
+23.67%
13.91
-33.04%
20.78
Other Gand A
20.27
+17.81%
17.20
+23.67%
13.91
-33.04%
20.78
Total Expenses
89.81
+32.99%
67.53
+5.25%
64.16
-0.92%
64.76
Operating Income
-89.81
-33.48%
-67.28
-119.37%
-30.67
+48.74%
-59.83
Total Operating Income As Reported
-89.81
-33.48%
-67.28
-119.37%
-30.67
+48.74%
-59.83
EBITDA
-87.21
-34.48%
-64.85
-128.31%
-28.41
+51.59%
-58.67
Normalized EBITDA
-87.21
-34.48%
-64.85
-128.31%
-28.41
+51.59%
-58.67
Reconciled Depreciation
2.60
+6.83%
2.43
+7.28%
2.27
+95.68%
1.16
EBIT
-89.81
-33.48%
-67.28
-119.37%
-30.67
+48.74%
-59.83
Total Unusual Items
—
3.60
+408.77%
0.71
—
Total Unusual Items Excluding Goodwill
—
3.60
+408.77%
0.71
—
Net Income
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Pretax Income
-83.86
-44.15%
-58.18
-77.95%
-32.69
+46.34%
-60.92
Net Non Operating Interest Income Expense
5.96
+11.40%
5.35
+311.01%
-2.54
-95.90%
-1.29
Interest Expense Non Operating
—
—
—
—
Net Interest Income
5.96
+11.40%
5.35
+311.01%
-2.54
-95.90%
-1.29
Interest Expense
—
—
—
—
Interest Income Non Operating
5.96
+11.40%
5.35
+311.01%
-2.54
-95.90%
-1.29
Interest Income
5.96
+11.40%
5.35
+311.01%
-2.54
-95.90%
-1.29
Other Income Expense
-0.01
-100.37%
3.75
+633.20%
0.51
+156.00%
0.20
Other Non Operating Income Expenses
-0.01
-100.37%
3.75
+633.20%
0.51
+156.00%
0.20
Gain On Sale Of Security
—
3.60
+408.77%
0.71
—
Tax Provision
—
0.00
-100.00%
0.07
+35.85%
0.05
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Net Income From Continuing Operation Net Minority Interest
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Net Income From Continuing And Discontinued Operation
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Net Income Continuous Operations
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Normalized Income
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Net Income Common Stockholders
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Diluted EPS
—
-5.81
-312.82%
-1.41
+78.39%
-6.51
Basic EPS
—
-5.81
-312.82%
-1.41
+78.39%
-6.51
Basic Average Shares
—
11.26
-51.64%
23.28
+148.69%
9.36
Diluted Average Shares
—
11.26
-51.64%
23.28
+148.69%
9.36
Diluted NI Availto Com Stockholders
-83.86
-44.15%
-58.18
-77.56%
-32.77
+46.26%
-60.98
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
130.94
-37.52%
209.58
+99.38%
105.11
-21.00%
133.05
Current Assets
112.67
-40.27%
188.63
+136.32%
79.82
-23.74%
104.67
Cash Cash Equivalents And Short Term Investments
108.01
-41.75%
185.43
+140.91%
76.97
-24.93%
102.53
Cash And Cash Equivalents
26.70
-33.64%
40.23
-24.80%
53.50
-47.82%
102.53
Other Short Term Investments
81.31
-44.00%
145.19
+518.71%
23.47
0.00
Receivables
0.07
-54.11%
0.15
-91.70%
1.76
+234.86%
0.53
Accounts Receivable
—
0.00
-100.00%
1.03
+96.95%
0.53
Other Receivables
0.01
-95.89%
0.15
+24.79%
0.12
—
Prepaid Assets
—
—
—
—
Other Current Assets
4.59
+50.18%
3.06
+179.95%
1.09
-32.55%
1.62
Total Non Current Assets
18.27
-12.77%
20.95
-17.17%
25.29
-10.86%
28.37
Net PPE
17.36
-15.03%
20.43
-17.12%
24.64
-10.75%
27.61
Gross PPE
25.81
-2.03%
26.35
-6.48%
28.18
-2.43%
28.88
Accumulated Depreciation
-8.46
-42.78%
-5.92
-67.70%
-3.53
-179.21%
-1.26
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.71
+14.78%
1.49
+0.68%
1.48
+0.75%
1.47
Other Properties
23.24
-4.96%
24.45
-7.06%
26.31
-3.02%
27.13
Leases
0.87
+111.46%
0.41
+5.13%
0.39
+37.81%
0.28
Non Current Deferred Assets
—
—
—
—
Other Non Current Assets
0.92
+75.05%
0.53
-19.23%
0.65
-14.70%
0.76
Total Liabilities Net Minority Interest
20.97
-8.59%
22.94
-91.41%
267.13
-2.42%
273.75
Current Liabilities
13.09
+6.81%
12.25
+0.21%
12.23
-52.28%
25.62
Payables And Accrued Expenses
9.96
+16.94%
8.51
-1.37%
8.63
-23.27%
11.25
Payables
0.35
-68.33%
1.12
+82.57%
0.61
-43.98%
1.10
Accounts Payable
0.35
-68.33%
1.12
+82.57%
0.61
-43.98%
1.10
Current Accrued Expenses
9.60
+29.87%
7.39
-7.80%
8.02
-21.03%
10.15
Current Debt And Capital Lease Obligation
3.06
-18.21%
3.74
+4.00%
3.60
+3.16%
3.49
Current Capital Lease Obligation
3.06
-18.21%
3.74
+4.00%
3.60
+3.16%
3.49
Current Deferred Liabilities
—
—
0.00
-100.00%
10.89
Current Deferred Revenue
—
—
0.00
-100.00%
10.89
Other Current Liabilities
0.07
—
—
—
Total Non Current Liabilities Net Minority Interest
7.88
-26.24%
10.69
-95.81%
254.90
+2.73%
248.12
Long Term Debt And Capital Lease Obligation
7.88
-25.73%
10.61
-20.29%
13.32
-16.58%
15.96
Long Term Capital Lease Obligation
7.88
-25.73%
10.61
-20.29%
13.32
-16.58%
15.96
Non Current Deferred Liabilities
—
—
0.00
-100.00%
15.63
Non Current Deferred Revenue
—
—
0.00
-100.00%
15.63
Other Non Current Liabilities
—
0.07
+0.00%
0.07
-36.52%
0.12
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
216.41
+0.00%
216.41
Stockholders Equity
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Common Stock Equity
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Capital Stock
0.00
+0.00%
0.00
0.00
0.00
Common Stock
0.00
+0.00%
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
24.60
+1.25%
24.29
+4.34%
23.28
+0.00%
23.28
Ordinary Shares Number
24.60
+1.25%
24.29
+4.34%
23.28
+0.00%
23.28
Additional Paid In Capital
440.41
+1.61%
433.45
+2182.76%
18.99
+59.63%
11.89
Retained Earnings
-330.55
-34.00%
-246.68
-36.06%
-181.31
-18.82%
-152.59
Gains Losses Not Affecting Retained Earnings
0.10
+179.84%
-0.13
-141.88%
0.31
0.00
Other Equity Adjustments
0.10
+179.84%
-0.13
-141.88%
0.31
—
Total Equity Gross Minority Interest
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Total Capitalization
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Working Capital
99.58
-43.54%
176.38
+160.94%
67.59
-14.49%
79.05
Invested Capital
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Total Debt
10.94
-23.77%
14.35
-15.13%
16.91
-13.04%
19.45
Capital Lease Obligations
10.94
-23.77%
14.35
-15.13%
16.91
-13.04%
19.45
Net Tangible Assets
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Tangible Book Value
109.97
-41.08%
186.64
+215.20%
-162.01
-15.15%
-140.70
Derivative Product Liabilities
—
0.00
-100.00%
25.10
0.00
Duefrom Related Parties Current
0.06
0.00
-100.00%
0.61
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-76.75
-39.47%
-55.03
-16.03%
-47.43
+6.69%
-50.83
Cash Flow From Continuing Operating Activities
-76.75
-39.47%
-55.03
-16.03%
-47.43
+6.69%
-50.83
Net Income From Continuing Operations
-83.86
-28.29%
-65.37
-127.62%
-28.72
+51.15%
-58.79
Depreciation Amortization Depletion
2.60
+6.83%
2.43
+7.28%
2.27
+95.68%
1.16
Depreciation And Amortization
2.60
+6.83%
2.43
+7.28%
2.27
+95.68%
1.16
Other Non Cash Items
—
—
—
—
Stock Based Compensation
6.82
-2.28%
6.98
-1.04%
7.05
+7.12%
6.58
Asset Impairment Charge
—
—
0.00
-100.00%
4.08
Operating Gains Losses
—
3.60
+408.77%
0.71
—
Gain Loss On Investment Securities
—
3.60
+408.77%
0.71
—
Change In Working Capital
-0.42
-30.46%
-0.33
+98.85%
-28.28
-631.51%
-3.87
Change In Receivables
0.08
-95.10%
1.61
+230.63%
-1.23
-2064.91%
-0.06
Changes In Account Receivables
0.00
-100.00%
1.03
+302.75%
-0.51
-794.74%
-0.06
Change In Prepaid Assets
-1.53
+21.93%
-1.97
-480.81%
0.52
+167.54%
-0.76
Change In Payables And Accrued Expense
1.24
+987.86%
-0.14
+89.39%
-1.32
-114.63%
-0.61
Change In Accrued Expense
2.00
+403.95%
-0.66
+27.74%
-0.91
-13.29%
-0.81
Change In Payable
-0.76
-246.44%
0.52
+227.21%
-0.41
-314.74%
0.19
Change In Account Payable
-0.76
-246.44%
0.52
+227.21%
-0.41
-314.74%
0.19
Change In Other Working Capital
-0.02
-148.84%
0.04
+100.16%
-26.38
-1007.05%
-2.38
Change In Other Current Assets
-0.19
-252.80%
0.12
-10.07%
0.14
+214.88%
-0.12
Change In Other Current Liabilities
—
—
0.00
-100.00%
0.07
Investing Cash Flow
63.41
+152.64%
-120.46
-363.77%
-25.98
-312.37%
-6.30
Cash Flow From Continuing Investing Activities
63.41
+152.64%
-120.46
-363.77%
-25.98
-312.37%
-6.30
Net PPE Purchase And Sale
-2.59
-302.96%
-0.64
+80.29%
-3.26
+48.28%
-6.30
Purchase Of PPE
-2.59
-302.96%
-0.64
+80.29%
-3.26
+48.28%
-6.30
Capital Expenditure
-2.59
-302.96%
-0.64
+80.29%
-3.26
+48.28%
-6.30
Net Investment Purchase And Sale
66.00
+155.08%
-119.82
-427.45%
-22.72
0.00
Purchase Of Investment
-44.88
+74.53%
-176.17
-255.78%
-49.52
0.00
Sale Of Investment
110.87
+96.76%
56.35
+110.26%
26.80
0.00
Financing Cash Flow
0.01
-99.99%
162.23
+565.11%
24.39
+2029.67%
-1.26
Cash Flow From Continuing Financing Activities
0.01
-99.99%
162.23
+565.11%
24.39
+2029.67%
-1.26
Net Issuance Payments Of Debt
-0.13
+11.41%
-0.15
0.00
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-0.13
+11.41%
-0.15
0.00
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-0.13
+11.41%
-0.15
0.00
—
Net Long Term Debt Issuance
-0.13
+11.41%
-0.15
0.00
—
Net Common Stock Issuance
0.00
-100.00%
162.32
+1352800.00%
-0.01
-140.00%
-0.01
Common Stock Payments
0.00
+100.00%
-4.18
-34758.33%
-0.01
-140.00%
-0.01
Repurchase Of Capital Stock
0.00
+100.00%
-4.18
-34758.33%
-0.01
-140.00%
-0.01
Proceeds From Stock Option Exercised
0.37
+627.45%
0.05
+410.00%
0.01
-96.99%
0.33
Net Other Financing Charges
-0.23
—
24.39
+1633.19%
-1.59
Changes In Cash
-13.33
-0.47%
-13.27
+72.93%
-49.01
+16.06%
-58.39
Beginning Cash Position
40.49
-24.68%
53.76
-47.69%
102.78
-36.23%
161.17
End Cash Position
27.16
-32.92%
40.49
-24.68%
53.76
-47.69%
102.78
Free Cash Flow
-79.34
-42.50%
-55.67
-9.84%
-50.69
+11.27%
-57.13
Income Tax Paid Supplemental Data
—
0.00
-100.00%
0.08
0.00
Amortization Of Securities
-1.88
+19.73%
-2.34
-413.60%
-0.46
0.00
Common Stock Issuance
0.00
-100.00%
166.51
0.00
—
Issuance Of Capital Stock
0.00
-100.00%
166.51
0.00
—
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category